Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)

NCT06462365 is registered in ClinicalTrials.gov with Tr1X, Inc. as lead sponsor.

NCT NCT06462365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06462365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
Lead sponsor
Tr1X, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 8, 2024
Completion date
April 15, 2027
Enrollment
36 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, adult b-cell, acute lymphoblastic leukemia, adult t-cell, acute myeloid leukemia in remission, cancer remission, chronic myelomonocytic leukemia, in remission, gvhd, gvhd, chronic, gvhd,acute, hematologic malignancy, hematopoietic stem cell transplant, myelodysplastic syndromes